XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Net revenues $ 4,164 $ 3,878 $ 7,983 $ 7,539
Cost of sales 2,140 2,082 4,188 4,161
Gross profit 2,024 1,796 3,795 3,378
Research and development expenses 269 240 511 473
Selling and marketing expenses 656 603 1,265 1,149
General and administrative expenses 283 307 561 602
Intangible assets impairments 61 63 141 241
Goodwill impairment 400 700 400 700
Other assets impairments, restructuring and other items [1] 280 108 954 218
Legal settlements and loss contingencies 83 462 188 695
Other income (2) (33) (1) (34)
Operating income (loss) [1] (5) (654) (223) (667)
Financial expenses, net 241 268 491 528
Income (loss) before income taxes [1] (246) (923) (713) (1,195)
Income taxes (benefit) 630 (16) 578 (35)
Share in (profits) losses of associated companies, net (2) (1) 2 (1)
Net income (loss) (874) (906) (1,294) (1,159)
Net income (loss) attributable to non-controlling interests (29) (35) (309) (68)
Net income (loss) attributable to Teva $ (846) $ (872) $ (985) $ (1,091)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ (0.75) $ (0.78) $ (0.87) $ (0.98)
Diluted $ (0.75) $ (0.78) $ (0.87) $ (0.98)
Weighted average number of shares (in millions):        
Basic 1,133 1,120 1,128 1,118
Diluted 1,133 1,120 1,128 1,118
[1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements.